Incretin & Metabolic Receptor Agonists
Tirzepatide
Also known as Mounjaro · Zepbound
Last reviewed: 2026-11-19
Evidence status & limitations
Large randomized trials support product-specific indications; population and formulation boundaries matter.
Regulatory status
FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.
Mounjaro · Type 2 Diabetes
Glycemic control in adults and children aged 10 and older with type 2 diabetes, with diet and physical activity.
Authoritative label recordZepbound · Weight Management
Long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition.
Authoritative label recordZepbound · Sleep Apnea
Moderate-to-severe obstructive sleep apnea in adults with obesity.
Authoritative label recordMounjaro · Cardiovascular Risk
Reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
Authoritative label record
Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.
WADA prohibited status: current list and contextKnown risks & open questions
Gastrointestinal symptoms, pancreatitis and gallbladder events are concerns; labeling includes a rodent thyroid C-cell tumor boxed warning.
Key sources
Targeted current-label and chronology check: November 19, 2026. Initial adult approval and later pediatric/cardiovascular expansions are distinct; trial summaries are not an exhaustive systematic review.
Related compounds
- Retatrutide
Same scientific class · A 39-amino-acid chain. · Late-stage human trials
- Semaglutide
Same scientific class · A 31-amino-acid chain. · FDA-approved for specific indications